Literature DB >> 26714369

WHO Expert Committee on Biological Standardization. Sixty-fifth report.

.   

Abstract

This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the adoption of international recommendations for the production and control of vaccines and other biological substances, and the establishment of international biological reference materials. Following a brief introduction, the report summarizes a number of general issues brought to the attention of the Committee. The next part of the report, of particular relevance to manufacturers and national regulatory authorities, outlines the discussions held on the development and adoption of new and revised WHO Recommendations, Guidelines and guidance documents. Following these discussions, a WHO guidance document on the Scientific principles for regulatory risk evaluation on finding an adventitious agent in a marketed vaccine was adopted along with WHO Guidelines on procedures and data requirements for changes to approved vaccines and revised WHO Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). Subsequent sections of the report provide information on the current status and proposed development of international reference materials in the areas of antibiotics; biotherapeutics other than blood products; blood products and related substances; in vitro diagnostic device reagents; and vaccines and related substances. A series of annexes are then presented which include an updated list of all WHO Recommendations, Guidelines and other documents on biological substances used in medicine (Annex 1) followed by the above three WHO documents adopted on the advice of the Committee (Annexes 2-4). All additions and discontinuations made during the 2014 meeting to the list of International Standards, Reference Reagents and Reference Panels for biological substances maintained by WHO are summarized in Annex 5. The updated full catalogue of WHO International Reference Preparations is available at: http://www.who.int/bloodproducts/catalogue/en/.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26714369

Source DB:  PubMed          Journal:  World Health Organ Tech Rep Ser        ISSN: 0512-3054


  7 in total

Review 1.  Biosimilar DMARDs: What Does the Future Hold?

Authors:  Filipe Araújo; João Gonçalves; João Eurico Fonseca
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

2.  A novel gamma radiation-inactivated sabin-based polio vaccine.

Authors:  Gregory J Tobin; John K Tobin; Elena K Gaidamakova; Taralyn J Wiggins; Ruth V Bushnell; Wai-Ming Lee; Vera Y Matrosova; Stephen J Dollery; Heather N Meeks; Diana Kouiavskaia; Konstantin Chumakov; Michael J Daly
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

3.  Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.

Authors:  Anna Lisa Ong-Lim; Georgi Shukarev; Mitzi Trinidad-Aseron; Delia Caparas-Yu; Astrid Greijer; Michel Duchene; Gert Scheper; Vitalija van Paassen; Mathieu Le Gars; Conor P Cahill; Hanneke Schuitemaker; Macaya Douoguih; Jeanne-Marie Jacquet
Journal:  Hum Vaccin Immunother       Date:  2022-03-28       Impact factor: 4.526

4.  Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps. A workshop Report.

Authors:  Laura Viviani; Kirsty Reid; Thierry Gastineau; Catherine Milne; Dean Smith; Robin Levis; Dianliang Lei; Mark van Ooij; Philippe Alexandre Gilbert; Joris Vandeputte; Jianxun Xie; Leena Madhuri; Shahjahan Shaid; Vaughn Kubiak; Rajinder Suri; Takuo Mizukami; Yoshihisa Shirasaki; Xiantang Li; Ying-Ying Zhou; Alla Trapkova; Sunil Goel; Jai Prakash; Amrullah Aninditio Subagio; Eniek Suwarni; Kyung Jin Jung; Gautam Sanyal; Pradip Das; Emmanuelle Coppens; David Wright; Zhechu Peng; Helle Northeved; Carmen Jungbäck; Tatiana Kirpitchenok; Lorenzo Del Pace; Borami Seo; Brinda Poojary; Antoniana Ottoni
Journal:  Biologicals       Date:  2022-07-12       Impact factor: 1.760

5.  Evaluation of the Potency of the Pertussis Vaccine in Experimental Infection Model with Bordetella pertussis: Study of the Case of the Pertussis Vaccine Used in the Expanded Vaccination Program in Algeria.

Authors:  Khedidja Tahar Djebbar; Mounia Allouache; Salim Kezzal; Fouzia Benguerguoura; Chafia TouilBoukoffa; Ines Zidi; Rachida Raache; Hadda-Imene Ouzari
Journal:  Vaccines (Basel)       Date:  2022-06-06

Review 6.  A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.

Authors:  Andrea Becciolini; Maria Gabriella Raimondo; Chiara Crotti; Elena Agape; Martina Biggioggero; Ennio Giulio Favalli
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

7.  Establishment of a WHO Reference Reagent for anti-Mullerian hormone.

Authors:  Jackie Ferguson; Jason Hockley; Peter Rigsby; Chris Burns
Journal:  Reprod Biol Endocrinol       Date:  2020-08-15       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.